11:52 AM EST - Resverlogix Corp. : announced that its Board of Directors has approved a proposal to spin out its subsidiary, RVX Therapeutics Inc., which will focus on innovative drug research and development by leveraging its epigenetics platform. RVX Therapeutics will exclude Apolipoprotein A-1 and RVX-208 technologies, rather focusing on multiple therapeutic indications including autoimmune diseases and cancer. Resverlogix Corp.
shares T.RVX are trading down $0.28 at $2.97.
